These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2225716)

  • 1. Effect of indecainide in patients with left ventricular dysfunction.
    Giardina EV; Saroff AL; Schneider M
    Clin Pharmacol Ther; 1990 Nov; 48(5):582-9. PubMed ID: 2225716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indecainide compared with quinidine for chronic stable ventricular arrhythmias secondary to coronary artery disease or to cardiomyopathy.
    Giardina EG; Zaim S; Saroff AL; Kirschenbaum M
    Am J Cardiol; 1987 Sep; 60(7):584-9. PubMed ID: 2442993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic effects of oral indecainide in patients with ventricular tachyarrhythmias.
    Macina G; Turitto G; Stavens C; Fontaine J; Hariman R; Ursell S; el-Sherif N
    Clin Cardiol; 1987 Jun; 10(6):357-61. PubMed ID: 3594958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indecainide for treatment of ventricular ectopic depolarizations: efficacy, pharmacokinetics, hemodynamic effects and safety.
    Salerno DM; Krejci J; Granrud G; Hodges M
    J Am Coll Cardiol; 1988 Apr; 11(4):843-50. PubMed ID: 3351153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia.
    Pratt CM; Francis MJ; Seals AA; Zoghbi W; Young JB
    Am J Cardiol; 1990 Jul; 66(1):68-74. PubMed ID: 2193498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia.
    Podrid PJ; Hohnloser S; Lown B
    Am J Cardiol; 1988 Apr; 61(10):764-9. PubMed ID: 2451415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiarrhythmic effects of indecainide in a drug-resistant population with ventricular tachycardia at programmed electrical stimulation.
    Miura DS; Wynn J; Keefe D; Laux B; Somberg JC
    Am Heart J; 1987 Jan; 113(1):65-9. PubMed ID: 3799443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of acute antiarrhythmic drug efficacy to left ventricular function in coronary artery disease.
    Meissner MD; Kay HR; Horowitz LN; Spielman SR; Greenspan AM; Kutalek SP
    Am J Cardiol; 1988 May; 61(13):1050-5. PubMed ID: 3284319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical electrophysiology of intravenous indecainide.
    Horowitz LN; Spielman SR; Webb CR; Morganroth J; Greenspan AM
    Am Heart J; 1985 Oct; 110(4):784-8. PubMed ID: 4050649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics.
    Holland DR; Lacefield WB; Gonzales CR; Johnston SR; Turk JA
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):454-61. PubMed ID: 2476626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of doxepin in cardiac patients with ventricular arrhythmias.
    Giardina EG; Cooper TB; Suckow R; Saroff AL
    Clin Pharmacol Ther; 1987 Jul; 42(1):20-7. PubMed ID: 3595065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of oral and intravenous indecainide in ventricular arrhythmias.
    Nestico PF; Morganroth J; Horowitz LN; Mulhern C
    Am J Cardiol; 1987 Jun; 59(15):1332-6. PubMed ID: 3296725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinidine pharmacodynamics in patients with arrhythmia: effects of left ventricular function.
    Gillis AM; Mitchell LB; Wyse DG; McDonald M; Duff HJ
    J Am Coll Cardiol; 1995 Apr; 25(5):989-94. PubMed ID: 7897143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term antiarrhythmic therapy with cibenzoline.
    Mohiuddin SM; Hilleman DE; Esterbrooks D; Mooss AN; Stengel LA
    J Clin Pharmacol; 1987; 27(5):400-6. PubMed ID: 3693585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.
    Hodges M; Haugland JM; Granrud G; Conard GJ; Asinger RW; Mikell FL; Krejci J
    Circulation; 1982 May; 65(5):879-85. PubMed ID: 7074749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cibenzoline for treatment of ventricular arrhythmias: a double-blind placebo-controlled study.
    Kostis JB; Krieger S; Moreyra A; Cosgrove N
    J Am Coll Cardiol; 1984 Aug; 4(2):372-7. PubMed ID: 6376595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on rabbit cardiac potentials of aprindine and indecainide, a new antiarrhythmic agent, in normoxia and hypoxia.
    Dennis PD; Vaughan Williams EM
    Br J Pharmacol; 1985 May; 85(1):11-9. PubMed ID: 4027460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral flecainide for suppression of ventricular arrhythmias.
    Vanhaleweyk G; Balakumaran K; Lubsen J; Roelandt J; Hugenholtz PG
    Cardiology; 1984; 71(1):30-9. PubMed ID: 6722846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirmenol for control of ventricular arrhythmias: oral dose-ranging and short-term maintenance study.
    Anderson JL; Lutz JR; Nappi JM
    Am J Cardiol; 1984 Feb; 53(4):522-7. PubMed ID: 6198894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerance of intravenous lorcainide in patients with normal and impaired intraventricular conduction.
    Stroobandt R; Kesteloot H
    Acta Cardiol; 1985; 40(6):637-48. PubMed ID: 3879420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.